Tirzepatide TFA (LY3298176 TFA, GIP and GLP-1 receptor agonist)-Therapeutic peptides drug benchmark for in-vivo/in-vitro study
Cat No.: GMP-Bios-peptide-001
Product Name: Tirzepatide TFA
Tirzepatide TFA, the trifluoroacetic acid salt form of Tirzepatide. Tirzepatide, a new glucose-lowering therapy for diabetes, is called a “dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist”. Drug company Lilly released important results showing that this new therapy may be extremely effective for people with type 2 diabetes. Across three clinical trials, tirzepatide reduced A1C by an average of 2.5 percentage points and led to a weight loss of about 25 pounds.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Product Name||Tirzepatide TFA|
|Brand name||NA (also known as LY3298176 TFA)|
|Biological Activity||Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.|
|Purity||Purity: ≥98% (HPLC)|
|Application||Therapeutic peptides drug benchmark or raw material for peptide drugs or peptide conjugation drugs discovery and development.|
|Predicted Molecular Mass||4927.47|
|Storage||Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.|